by Pinrae Jonsson
Pfizer has announced that it has an early intervention antiviral drug for COVID treatment, and the possibilities are intriguing.
One of the most peculiar things about COVID in America is that the powers that be — in politics, media, and medicine — have been hostile to the possibility of treating COVID. Since the virus emerged, people have been told there's nothing that can be done to treat COVID until they're near death, at which point...there's nothing that can be done to treat COVID. These same actors have hysterically opposed both the hydroxychloroquine cocktail and ivermectin. However, that resistance to early intervention may change now that Pfizer has a COVID-19 therapeutic antiviral protease inhibitor called PF-07321332.
PF-07321332 entered its phase two and three trials in August 2021. The treatment will be administered orally, although another version, called PF-07304814, is administered through an IV drip. According to Pfizer:
We believe that, if successful and authorized or approved, these investigational therapies could provide end-to-end treatment options for COVID-19 patients, including those exposed to the virus, those with diagnosed infections treated in the outpatient setting, and those hospitalized with moderate to severe infection.
Antiviral medications operate by interfering with a virus's ability to replicate in the body. If the medication is given early enough in the illness's progress, the infection will be weak. Protease inhibitors and other antivirals have been around for a long time for treating various illnesses, but they've only had off-label use in treating COVID cases. Pfizer's version, however, would be specific to SARS-CoV-2 treatment.
Early in the pandemic, existing antivirals, especially protease inhibitors, intrigued scientists. That's because they'd noticed that HIV patients already taking protease inhibitors for AIDS disease, if they caught COVID, mostly had surprisingly mild cases and unexpected survival rates. Also, in 2003, an earlier coronavirus — SARS-CoV-1 — responded well to protease inhibitors. Pfizer explained, "In preclinical in vitro studies, many of the SARS-CoV-1 protease inhibitors identified in 2003 were found to also inhibit the SARS-CoV-2 protease."
Even viewed in the best possible light, the mRNA vaccine, while a modern marvel, is a vastly impractical answer for an ever-changing virus. The mu variant came from Colombia. The delta variant came from India. More variants can be expected to come across our border, creating new, ever-changing complications and challenges. Unless America is going to vaccinate every single citizen and non-citizen within our borders and close off from the rest of the world for the next few decades, variants will not stop.
Because antiviral protease inhibitors disrupt viral replication, creating a mild disease, and because mild diseases will create antibodies in the main citizenry and rapid acceleration of herd immunity country-wide, protease inhibitors should be a topic of current interest and discussion.
Biden's vaccine mandates not only are unconstitutional but they also provide no lasting solution. And perhaps because this protease inhibitor is from Pfizer, and is new and exciting, the usual suspects will stop fighting it and finally let people get treated immediately if they catch COVID.
Pinrae Jonsson is a pseudonym.
Image: Exploding pills by qimono. Pixabay license.
Pinrae Jonsson
Source: https://www.americanthinker.com/blog/2021/09/at_long_last_there_might_be_a_covid_treatment_leftists_wont_denigrate.html
No comments:
Post a Comment